Medline (MDLN) Cash & Equivalents (2024 - 2026)

Medline (MDLN) has 3 years of Cash & Equivalents data on file, last reported at $2.2 billion in Q1 2026.

• On a quarterly basis, Cash & Equivalents changed N/A year-over-year to $2.2 billion in Q1 2026; TTM through Mar 2026 was $2.2 billion, a N/A change from a year earlier, with the FY2025 full-year figure at $1.9 billion, up 874.37% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $2.2 billion, up from $1.9 billion in the prior quarter.
• Over the last five years, Cash & Equivalents for MDLN reached as high as $2.2 billion in Q1 2026 and fell as low as $199.0 million in Q4 2024.
• Historically, Cash & Equivalents has averaged $1.5 billion across 3 years, with a median of $1.9 billion in 2025.
• On a YoY basis, Cash & Equivalents climbed as much as 874.37% in 2025 and fell as far as 874.37% in 2025.
• Year by year, Cash & Equivalents stood at $199.0 million in 2024, then soared by 874.37% to $1.9 billion in 2025, then increased by 15.32% to $2.2 billion in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $2.2 billion in Q1 2026, $1.9 billion in Q4 2025, and $199.0 million in Q4 2024.